Therapeutic Options and Prognostic Factors in Treatment of Anaplastic Gliomas

1. Roth, Christian Hartmann et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology 2016; 18(11), 1529–1537.Search in Google Scholar

2. Vincent T. DeVita Jr. MD, Theodore S. Lawrence PhD, MD, Steven A. Rosenberg MD, PhD: Principles & Practice of Oncology,10th edition, Wolters Kluwer Health, 2015.Search in Google Scholar

3. David N. Louis et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System.2016; 131:803–820.10.1007/s00401-016-1545-1Search in Google Scholar

4. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet. 2012;379(9830):1984-1996.10.1016/S0140-6736(11)61346-9Search in Google Scholar

5. Tortosa A, Viñolas N, Villà S, et al. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer. 2003;97(4): 1063-1071.10.1002/cncr.11120Search in Google Scholar

6. Dolecek TA et al. Primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 2012; 14:v1–v49.10.1093/neuonc/nos218Search in Google Scholar

7. Compostella A, Tosoni A, Blatt V, Franceschi E, Brandes AA. Prognostic factors for anaplastic astrocytomas. J Neurooncol. 2007;81(3):295-303.10.1007/s11060-006-9232-zSearch in Google Scholar

8. McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156-162.10.3171/2008.4.17536Search in Google Scholar

9. Rogne SG et al. Anaplastic astrocytomas: survival and prognostic factors in a surgical series. Acta Neurochir. 2014; 156(6):1053-61.10.1007/s00701-014-2053-5Search in Google Scholar

10. Prados MD, Gutin PH, Phillips TL, et al. Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int J Radiat Oncol Biol Phys. 1992; 23(1):3-8.10.1016/0360-3016(92)90537-RSearch in Google Scholar

11. Liang BC, Thornton AF, Sandler HM, Greenberg HS. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg. 1991;75(4):559-563.10.3171/jns.1991.75.4.05591653309Search in Google Scholar

12. Korshunov A, Golanov A, Sycheva R. Immunohistochemical markers for prognosis of anaplastic astrocytomas. J Neurooncol. 2002;58(3):203-215.10.1023/A:1016261900413Search in Google Scholar

13. Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Neuro Oncol. 2012;14(1):109-116.10.1093/neuonc/nor185324599822039037Search in Google Scholar

14. Sallinen PK, Haapasalo HK, Visakorpi T, et al. Prognostication of astrocytoma patient survival by Ki-67 (MIB- 1), PCNA, and S-phase fraction using archival paraffinembedded samples. J Pathol. 1994;174(4):275-282.10.1002/path.17117404077884589Search in Google Scholar

15. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120 (6):707-718.10.1007/s00401-010-0781-z21088844Search in Google Scholar

16. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93(16):1246-125610.1093/jnci/93.16.124611504770Search in Google Scholar

17. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337-343.10.1200/JCO.2012.43.2674373201223071247Search in Google Scholar

18. Maria Teresa Solomon et al. Nimotuzumab in combination with radiotherapy in high grade glioma patients, Cancer Biology & Therapy. (2014); 15:5, 504–509.10.4161/cbt.28021402607224521695Search in Google Scholar

19. Ohgaki H, Kleihues P Genetic pathways to primary and secondary glioblastoma.Am J Pathol. (2007). 170(5):1445-53.10.2353/ajpath.2007.070011185494017456751Search in Google Scholar

20. Valiyaveettil D, Malik M, Joseph D, Ahmed SF, Kothwal SA. Prognostic factors and outcomes in anaplastic gliomas: An institutional experience. South Asian J Cancer. 2018;7(1):1-4.10.4103/sajc.sajc_55_17586508529600221Search in Google Scholar

21. Reuss DE, Mamatjan Y, Schrimpf D,Capper D, Hovestadt V, Kratz A, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. (2015) 129(6):867-73.10.1007/s00401-015-1438-8450003925962792Search in Google Scholar